I actually doubled down on AEZS and sold a few shares of IMGN to do so, I believe it's greatly oversold, given the size of the pipeline and trials in place, concluded with NDA's to follow, as well as the Phase III in AEZS-108 to be initiated probably late this year. As we've learned over the years with IMGN, nothing happens quickly, but good things are happening with both companies. I reasoned that AEZS could easily triple or better from where it is today before IMGN can double, while I expect both to happen, AEZS was worth taking a further bet on.
Frankly the trial which short term may say a lot about AEZS may be the Cancer Cachexia Phase II Trial. If early data says the drug has benefits in this area, what is judged to be purely a niche product could grow dramatically. If approved for HGH deficiency analysis, it could be used off label until full approval is given.
As for IMGN, the next big news will be either the NDA being filed, or it being accepted. I'm unsure if the filing will even be announced, but believe its acceptance will bring a milestone payment which must be announced. If it were Genentech running things, I believe they'd be more open, but Roche probably will limit what's said to what must be.
Gary |
